SCHEMBL20171814

SCHEMBL20171814

C=C(O)c1ccc(-c2nc(NC=O)cc3ccccc23)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.36
ADORA3 P0DMS8 2/20 0.33
MAP2K4 P45985 1/20 0.33
ALDH1A1 P00352 5/20 0.32
HPGD P15428 5/20 0.32
KDM4E B2RXH2 4/20 0.32
CYP1A2 P05177 3/20 0.32
CYP2C19 P33261 3/20 0.32
CYP2C9 P11712 2/20 0.32
GAA P10253 2/20 0.32
CYP3A4 P08684 1/20 0.32
HSD17B10 Q99714 2/20 0.32
TSHR P16473 1/20 0.32
KDR P35968 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
HDAC1 Q13547 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19418868 0.88 MAP2K4 (0.45) MAP2K4ALDH1A1HPGDKDM4EGAA
SCHEMBL27748860 0.70 TSPO (0.43) ALDH1A1KDM4ECYP2C9GAACYP3A4
SCHEMBL13804185 0.67 NUDT1 (0.53) ALDH1A1HPGDKDM4ECYP1A2CYP2C19
SCHEMBL3969357 0.66 MAP2K4 (0.46) MAP2K4ALDH1A1HPGDKDM4ECYP1A2
SCHEMBL1998972 0.65 KDM4E (0.42) ALDH1A1HPGDKDM4ECYP1A2GAA
SCHEMBL213577 0.64 MYC (0.41) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL21312018 0.64 GAA (0.52) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL15616223 0.63 TNKS (0.56) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL4829403 0.62 ADORA1 (0.58) ADORA3MEN1KMT2A
SCHEMBL28100413 0.62 SLC2A1 (0.46) ALDH1A1HPGDKDM4ETSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3424534-B1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES VERTEX PHARMA (US) 2021-06-02 EP disclosed
EP-3131582-B1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES VERTEX PHARMA (US) 2018-05-23 EP disclosed